Plant secondary metabolites are produced and selected by evolution for their biological
activity. Such natural products have always played a major role in traditional medicine
and as leads for modern medicine. Only a small fraction of the Worlds biodiversity
has been explored for chemical and biological activity. A correlation between phylogeny
and biosynthetic pathways is often assumed and could offer a predictive approach enabling
more efficient selection of plants for traditional medicine lead discovery. However,
formal tests of correlations between phylogeny and chemistry are rare, and the potential
predictive power is consequently unknown. As a case in point, we are exploring the
Amaryllidaceae subfamily Amaryllidoideae sensu APG, which is known for subfamily specific
alkaloids with activity in the central nervous system (CNS). Galanthamine registered
for the treatment of Alzheimer's disease was first isolated from the Caucasian snowdrop
Galanthus woronowii Losinsk. We present a phylogenetic hypothesis of the Amaryllidaceae subfamily Amaryllidoideae
based on nuclear, plastid and mitochondrial DNA sequences of over 100 of the circa
850 species, representing all tribes and geographical regions. All major lineages
are now well supported and the extended sampling uncovered several genera as non-monophyletic,
emphasizing the importance of using phylogenetic rather than classical classification
for interpretation of character distribution. Alkaloid profiles and CNS-related bioactivity
profiles are significantly correlated with phylogeny using formal tests. Relationships
between phylogenetic and chemical diversity are further explored. The predictive power
can be used to select candidate taxa for lead discovery and to make recommendations
for traditional use.
Keywords: Amaryllidaceae, phylogeny, chemical diversity, lead discovery
Acknowledgement:
This research was supported by a Steno grant (N°272–07–0281) to NR from the Danish
Council for Independent Research – Natural Sciences.